ProMIS Neurosciences Soars on First Nasdaq Trading Day

Newly uplisted biotech, ProMIS Neurosciences (Nasdaq: PMN)(TSX: PMN), soared on its first day of trading on Nasdaq, on Friday 8 July, closing up 44%.

ProMIS is focused on developing antibody therapeutics for neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease and multisystem atrophy (MSA). Neurodegenerative diseases are ultimately fatal and have no cure.


  •  ProMIS enjoyed a stellar first day of trading and has performed solidly during the week;
  • The company reached a high of $13.20 and has seen a price increase of 57% over the past month;
  • ProMIS expects to enter the clinic in early 2023 with its first drug candidate, PMN310 to address one of the world’s largest unmet medical needs, Alzheimer’s disease;
  • CEO, Eugene Williams, thanked Canadian and US investors for their support and said the company’s mission is to “make significant contributions to treating neurodegenerative diseases.”

ProMIS rang the closing bell at Nasdaq on Wednesday 13 July. The company has a proud Canadian history and is dual listed on the Toronto Stock Exchange and Nasdaq.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

ProMIS Neurosciences Soars on First Nasdaq Trading Day

Editor Prism MarketView